
Syndax Pharmaceuticals Inc SNDX
Syndax Pharmaceuticals Inc statistics & valuation
P / B29.2×
Net margin-165.6%
FCF margin-187.5%
Return on capital-66.7%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Net margin (%)Gross margin (%)Operating margin (%)Return on equity (%)Shares outstandingNet debt ($)Share buybacks ($)Return on assets (%)Free cash flow margin (%)Debt / equity (×)EPS ($) Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|
| Operating margin | -158.4% | -1434.4% | — | — | 18.8% | -4708.2% | -3792.9% | -5001.7% | -2939.0% | -3587.4% |
| Net margin | -165.6% | -1346.1% | — | — | 17.8% | -4822.5% | -3694.6% | -4875.5% | -2884.3% | -3645.2% |
| FCF margin | -187.5% | -1160.9% | — | — | 20.8% | -4697.4% | — | -4529.9% | -2251.2% | -2903.1% |
| Return on assets | -53.9% | -44.0% | -34.2% | -30.0% | 5.5% | -24.3% | -88.2% | -88.1% | -44.3% | -40.8% |
| Return on equity | -441.6% | -110.6% | -37.8% | -31.9% | 6.1% | -29.0% | -177.4% | -139.4% | -58.3% | -52.9% |
| Current ratio | 4.40 | 5.82 | 10.00 | 16.85 | 21.68 | 15.84 | 3.39 | 5.18 | 8.45 | 10.47 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.